PADI4

Across TCGA pan-cancer cohorts, PADI4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PADI4 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PADI4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PADI4 expression acts as an unfavorable survival marker, although some lineages such as OV and UCEC show a favorable association.

LUAD, OV, and COAD are the cancer types where PADI4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.216	0.661	.007	15	view →
OV	DFS	Tertile	All	0.923	0.688	.045	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	4	view →
HNSC	DFS	Median	III,IV	0.706	0.899	.033	3	view →
CCRCC	DFS	Quartile	III,IV	0.078	0.904	.038	3	view →
LSCC	DFS	Quartile	All	0.839	0.353	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PADI4–LUAD (OS)

Open the LUAD breakdown →